210 related articles for article (PubMed ID: 16033770)
1. Breast carcinomas fulfill the Warburg hypothesis and provide metabolic markers of cancer prognosis.
Isidoro A; Casado E; Redondo A; Acebo P; Espinosa E; Alonso AM; Cejas P; Hardisson D; Fresno Vara JA; Belda-Iniesta C; González-Barón M; Cuezva JM
Carcinogenesis; 2005 Dec; 26(12):2095-104. PubMed ID: 16033770
[TBL] [Abstract][Full Text] [Related]
2. The bioenergetic signature of lung adenocarcinomas is a molecular marker of cancer diagnosis and prognosis.
Cuezva JM; Chen G; Alonso AM; Isidoro A; Misek DE; Hanash SM; Beer DG
Carcinogenesis; 2004 Jul; 25(7):1157-63. PubMed ID: 14963017
[TBL] [Abstract][Full Text] [Related]
3. Alteration of the bioenergetic phenotype of mitochondria is a hallmark of breast, gastric, lung and oesophageal cancer.
Isidoro A; Martínez M; Fernández PL; Ortega AD; Santamaría G; Chamorro M; Reed JC; Cuezva JM
Biochem J; 2004 Feb; 378(Pt 1):17-20. PubMed ID: 14683524
[TBL] [Abstract][Full Text] [Related]
4. HuR and the bioenergetic signature of breast cancer: a low tumor expression of the RNA-binding protein predicts a higher risk of disease recurrence.
Ortega AD; Sala S; Espinosa E; González-Barón M; Cuezva JM
Carcinogenesis; 2008 Nov; 29(11):2053-61. PubMed ID: 18687667
[TBL] [Abstract][Full Text] [Related]
5. FOXA1 expression in breast cancer--correlation with luminal subtype A and survival.
Badve S; Turbin D; Thorat MA; Morimiya A; Nielsen TO; Perou CM; Dunn S; Huntsman DG; Nakshatri H
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4415-21. PubMed ID: 17671124
[TBL] [Abstract][Full Text] [Related]
6. [Expression and prognostic value of transcriptional factor sp1 in breast cancer].
Wang XB; Peng WQ; Yi ZJ; Zhu SL; Gan QH
Ai Zheng; 2007 Sep; 26(9):996-1000. PubMed ID: 17927860
[TBL] [Abstract][Full Text] [Related]
7. REG1A expression is an independent factor predictive of poor prognosis in patients with breast cancer.
Sasaki Y; Minamiya Y; Takahashi N; Nakagawa T; Katayose Y; Ito A; Saito H; Motoyama S; Ogawa J
Ann Surg Oncol; 2008 Nov; 15(11):3244-51. PubMed ID: 18781363
[TBL] [Abstract][Full Text] [Related]
8. Microarray analysis of altered sphingolipid metabolism reveals prognostic significance of sphingosine kinase 1 in breast cancer.
Ruckhäberle E; Rody A; Engels K; Gaetje R; von Minckwitz G; Schiffmann S; Grösch S; Geisslinger G; Holtrich U; Karn T; Kaufmann M
Breast Cancer Res Treat; 2008 Nov; 112(1):41-52. PubMed ID: 18058224
[TBL] [Abstract][Full Text] [Related]
9. BigH3 protein expression as a marker for breast cancer.
Calaf GM; Echiburú-Chau C; Zhao YL; Hei TK
Int J Mol Med; 2008 May; 21(5):561-8. PubMed ID: 18425347
[TBL] [Abstract][Full Text] [Related]
10. Increased expression of urokinase-type plasminogen activator mRNA determines adverse prognosis in ErbB2-positive primary breast cancer.
Urban P; Vuaroqueaux V; Labuhn M; Delorenzi M; Wirapati P; Wight E; Senn HJ; Benz C; Eppenberger U; Eppenberger-Castori S
J Clin Oncol; 2006 Sep; 24(26):4245-53. PubMed ID: 16963728
[TBL] [Abstract][Full Text] [Related]
11. Poor-prognosis estrogen receptor-positive breast cancer identified by histopathologic subclassification.
Webster LR; Lee SF; Ringland C; Morey AL; Hanby AM; Morgan G; Byth K; Mote PA; Provan PJ; Ellis IO; Green AR; Lamoury G; Ravdin P; Clarke CL; Ward RL; Balleine RL; Hawkins NJ
Clin Cancer Res; 2008 Oct; 14(20):6625-33. PubMed ID: 18927304
[TBL] [Abstract][Full Text] [Related]
12. [Molecular-biological markers as prognostic factors in breast cancer of I-IIA stage].
Stepanova EV; Zagrekova EI; Ermilova VD; Turbin AD; Petrovichev NN; Vysotskaia IV; Dbar ZhN; Pashchenko NV; Baryshnikov AIu; Lichinitser MR
Arkh Patol; 2003; 65(3):14-8. PubMed ID: 12879604
[TBL] [Abstract][Full Text] [Related]
13. Is tissue inhibitor of metalloproteinase-1 a new prognosticator for breast cancer? An analysis of 266 cases.
Neri A; Megha T; Bettarini F; Tacchini D; Mastrogiulio MG; Marrelli D; Pinto E; Tosi P
Hum Pathol; 2012 Aug; 43(8):1184-91. PubMed ID: 22397869
[TBL] [Abstract][Full Text] [Related]
14. Expression of periostin in human breast cancer.
Puglisi F; Puppin C; Pegolo E; Andreetta C; Pascoletti G; D'Aurizio F; Pandolfi M; Fasola G; Piga A; Damante G; Di Loreto C
J Clin Pathol; 2008 Apr; 61(4):494-8. PubMed ID: 17938160
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of caveolin-1 and -2 in cell lines and in human samples of inflammatory breast cancer.
Van den Eynden GG; Van Laere SJ; Van der Auwera I; Merajver SD; Van Marck EA; van Dam P; Vermeulen PB; Dirix LY; van Golen KL
Breast Cancer Res Treat; 2006 Feb; 95(3):219-28. PubMed ID: 16244790
[TBL] [Abstract][Full Text] [Related]
16. Breast cancer patients with p53 Pro72 homozygous genotype have a poorer survival.
Tommiska J; Eerola H; Heinonen M; Salonen L; Kaare M; Tallila J; Ristimäki A; von Smitten K; Aittomäki K; Heikkilä P; Blomqvist C; Nevanlinna H
Clin Cancer Res; 2005 Jul; 11(14):5098-103. PubMed ID: 16033823
[TBL] [Abstract][Full Text] [Related]
17. Study of the topographic distribution of ets-1 protein expression in invasive breast carcinomas in relation to tumor phenotype.
Mylona EE; Alexandrou PT; Giannopoulou IA; Rafailidis PI; Markaki S; Keramopoulos A; Nakopoulou LL
Cancer Detect Prev; 2006; 30(2):111-7. PubMed ID: 16632244
[TBL] [Abstract][Full Text] [Related]
18. C-erbB-2 expression is a better predictor for survival than galectin-3 or p53 in early-stage breast cancer.
Logullo AF; Lopes AB; Nonogaki S; Soares FA; Netto MM; Nishimoto IN; Brentani MM
Oncol Rep; 2007 Jul; 18(1):121-6. PubMed ID: 17549356
[TBL] [Abstract][Full Text] [Related]
19. E-cadherin status in breast cancer correlates with histologic type but does not correlate with established prognostic parameters.
Qureshi HS; Linden MD; Divine G; Raju UB
Am J Clin Pathol; 2006 Mar; 125(3):377-85. PubMed ID: 16613340
[TBL] [Abstract][Full Text] [Related]
20. Aberrant expression of cyclin E in low-risk node negative breast cancer.
Ahlin C; Gruhne B; Holmqvist M; Zetterberg A; Fjällskog ML
Acta Oncol; 2008; 47(8):1539-45. PubMed ID: 18607847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
